NSEGeneral Updates18h ago · 15 Sept 2026, 07:53 pm

General Updates

Mankind Pharma Limited · MANKIND

✦ AI SummaryESG

Mankind Pharma Limited has informed the Exchange about its ESG Rating, which was assigned by Niche99 ESG Ratings as 68.21 under the 'Leader' category for FY 2025-26.

Analysis Scores

Earnings Impact1/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Mankind Pharma Limited has informed the Exchange about ESG Rating

Attachments (1)

📄

MANKIND1_15092026195248_ESGRatings.pdf

pdf

Download →
View document text
September 15, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Intimation of Environmental, Social and Governance (ESG) Rating Ref.: Regulation 30 & 51 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) Pursuant to Regulations 30 and 51 of the Listing Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, we wish to inform you that Niche99 ESG Ratings, a SEBI registered Category II ESG Rating Provider (“Niche99”) has assigned the Company the rating of 68.21, under “Leader” category based on the disclosures and data available in public domain for FY 2025-26. Please note that the Company has not engaged Niche99 for ESG Ratings and that it has independently prepared the report. The above disclosure is also being made available on the Company’s website at www.mankindpharma.com. This is for your information and records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer